<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty patients, with mainly poor risk <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, were given the new regimen FLAG, comprising fludarabine, arabinosyl <z:chebi fb="1" ids="16040">cytosine</z:chebi> and G-CSF </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty four patients had <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 8 patients <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and a further 8 patients had a variety of other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The response rates for 19 relapsed and 4 refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients were 68% and 100% respectively and comparable to those attained using other regimens, although the numbers are small </plain></SENT>
<SENT sid="3" pm="."><plain>Of 8 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 7 showed some response with 4 remaining in an improved disease status 5-12 months after FLAG </plain></SENT>
<SENT sid="4" pm="."><plain>Follow-up has been too short thus far to provide any survival data in both patient groups </plain></SENT>
<SENT sid="5" pm="."><plain>In general, the other smaller group of 8 patients (3 transformed <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>), 3 <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL), 2 granulocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (GS) did poorly with response shown in 1 only </plain></SENT>
<SENT sid="6" pm="."><plain>The regimen was well tolerated with 4 procedure-related neutropenic <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The neutropenic and thrombocytopenic periods are generally short when compared with those from current protocols </plain></SENT>
<SENT sid="8" pm="."><plain>The overall modest toxicity may encourage combination with other anti-leukaemic agents and be of particular use in the aged or heavily pre-treated patients </plain></SENT>
<SENT sid="9" pm="."><plain>Preliminary results may favour the setting up of controlled trials to properly evaluate the benefit of FLAG </plain></SENT>
</text></document>